That's the power you have with KBI and Selexis.
That's the power of together.
There is a global need for high-quality, effective, off-the-shelf therapies that can be used immediately, while concurrently avoiding supply chain issues and mitigating process complexities. Bispecific antibodies (bsAbs) are constructed to help meet this need due to their ability to bind to two or more different epitopes, thereby allowing them to perform multiple discrete mechanisms of action.
The KBI-Selexis partnership offers far more beyond the combination of best-in-class CLD with unparalleled expertise and experience in mammalian-based contract development and manufacturing. These highly productive "client-to-industry" collaborations prioritize quality, efficiencies, and time savings in bsAb production across a diverse portfolio of molecule formats to strengthen client programs.
KBI & Selexis: Offering Industry-leading delivery of bispecific programs through increased quality, efficiency, and time savings.
“
We have always been a science driven, customer centric company. The KBI-Selexis integration helps our clients optimize their complex biomanufacturing processes under accelerated timelines.
”
“
Together, KBI and Selexis have successfully completed more than 65 integrated programs, including projects for mAbs, bsAbs, tri-specifics, and Fc-fusions.
”
“
Our KBI-Selexis integrated programs typically have very aggressive and expedited timelines, and our coordination and close collaboration have proven to be essential for the success of these programs.
”
“
With a single touchpoint for best-in-class cell line development, process development, and manufacturing, clients experience heightened access to our process and product-based expertise.
”
© 2024 KBI Biopharma